Résultats de la recherche - Spring, Laura
- Résultat(s) 1 - 20 résultats de 29
- Aller à la page suivante
-
1
Targeting the cyclin D–cyclin-dependent kinase (CDK)4/6–retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current stat... par Spring, Laura, Bardia, Aditya, Modi, Shanu
Publié 2016Texte -
2
-
3
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations par Spring, Laura M., Zangardi, Mark L., Moy, Beverly, Bardia, Aditya
Publié 2017Texte -
4
-
5
-
6
Stevens-Johnson syndrome–like eruption from palbociclib in a patient with metastatic breast cancer par Karagounis, Theodora, Vallurupalli, Mounica, Nathan, Neera, Nazarian, Rosalynn, Vedak, Priyanka, Spring, Laura, Chen, Steven T.
Publié 2018Texte -
7
Sacituzumab Govitecan for Metastatic Triple‐Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities par Spring, Laura M., Nakajima, Erika, Hutchinson, Jennifer, Viscosi, Elene, Blouin, Gayle, Weekes, Colin, Rugo, Hope, Moy, Beverly, Bardia, Aditya
Publié 2021Texte -
8
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis par Spring, Laura M., Gupta, Arjun, Reynolds, Kerry L., Gadd, Michele A., Ellisen, Leif W., Isakoff, Steven J., Moy, Beverly, Bardia, Aditya
Publié 2016Texte -
9
Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series par Gazourian, Lee, Spring, Laura, Meserve, Emily, Hwang, David, Diaz, Alejandro A., Ash, Samuel Y., Ho, Vincent T., Sholl, Lynette M., Washko, George R.
Publié 2017Texte -
10
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic par Spring, Laura M., Specht, Michelle C., Jimenez, Rachel B., Isakoff, Steven J., Wang, Gary X., Ly, Amy, Shin, Jennifer A., Bardia, Aditya, Moy, Beverly
Publié 2020Texte -
11
A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry par Smith, Barbara L., Nguyen, Anvy, Korotkin, Jenna E., Kelly, Bridget N., Specht, Michelle C., Spring, Laura M., Moy, Beverly, Isakoff, Steven J., Gadd, Michele A.
Publié 2020Texte -
12
Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer par Bychkovsky, Brittany L., Guo, Hao, Sutton, Jazmine, Spring, Laura, Faig, Jennifer, Dagogo-Jack, Ibiayi, Battelli, Chiara, Houlihan, Mary Jane, Yeh, Tsai-Chu, Come, Steven E., Lin, Nancy U.
Publié 2016Texte -
13
Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis par Spring, Laura M., Fell, Geoffrey, Arfe, Andrea, Sharma, Chandni, Greenup, Rachel, Reynolds, Kerry L., Smith, Barbara L., Alexander, Brian, Moy, Beverly, Isakoff, Steven J., Parmigiani, Giovanni, Trippa, Lorenzo, Bardia, Aditya
Publié 2020Texte -
14
Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion par Mortensen, Lindsey, Ordulu, Zehra, Dagogo‐Jack, Ibiayi, Bossuyt, Veerle, Winters, Loren, Taghian, Alphonse, Smith, Barbara L., Ellisen, Leif W., Kiedrowski, Lesli A., Lennerz, Jochen K., Bardia, Aditya, Spring, Laura M.
Publié 2021Texte -
15
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer par Spring, Laura M., Clark, Shealagh L., Li, Tianyu, Goel, Shom, Tayob, Nabihah, Viscosi, Elene, Abraham, Elizabeth, Juric, Dejan, Isakoff, Steven J., Mayer, Erica, Moy, Beverly, Supko, Jeffrey G., Tolaney, Sara M., Bardia, Aditya
Publié 2021Texte -
16
Effectiveness and tolerability of neoadjuvant pertuzumab containing regimens for HER2-positive localized breast cancer. par Spring, Laura, Niemierko, Andrzej, Haddad, Stephanie, Yuen, Megan, Comander, Amy, Reynolds, Kerry, Shin, Jennifer, Bahn, Atul, Brachtel, Elena, Specht, Michelle, Smith, Barbara L., Taghian, Alphonse, Jimenez, Rachel, Peppercorn, Jeffrey, Isakoff, Steven J., Moy, Beverly, Bardia, Aditya
Publié 2018Texte -
17
FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer par Drago, Josh, Formisano, Luigi, Juric, Dejan, Niemierko, Andrzej, Servetto, Alberto, Wander, Seth, Spring, Laura, Vidula, Neelima, Peppercorn, Jeffrey, Younger, Jerry, Malvarosa, Giuliana, Yuen, Megan, Sgroi, Dennis, Isakoff, Steven J., Moy, Beverly, Ellisen, Leif W., Iafrate, John, Arteaga, Carlos L., Bardia, Aditya
Publié 2019Texte -
18
Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses par Koh, Siang-Boon, Dontchos, Brian N., Bossuyt, Veerle, Edmonds, Christine, Cristea, Simona, Melkonjan, Nsan, Mortensen, Lindsey, Ma, Annie, Beyerlin, Kassidy, Denault, Elyssa, Niehoff, Elizabeth, Hirz, Taghreed, Sykes, David B., Michor, Franziska, Specht, Michelle, Lehman, Constance, Ellisen, Leif W., Spring, Laura M.
Publié 2021Texte -
19
A digital RNA signature of Circulating Tumor Cells predicting early therapeutic response in localized and metastatic breast cancer par Kwan, Tanya T., Bardia, Aditya, Spring, Laura M., Giobbie-Hurder, Anita, Kalinich, Mark, Dubash, Taronish, Sundaresan, Tilak, Hong, Xin, LiCausi, Joseph A., Ho, Uyen, Silva, Erin J., Wittner, Ben S., Sequist, Lecia V., Kapur, Ravi, Miyamoto, David T., Toner, Mehmet, Haber, Daniel A., Maheswaran, Shyamala
Publié 2018Texte -
20
Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy par Griffiths, Jason I., Chen, Jinfeng, Cosgrove, Patrick A., O’Dea, Anne, Sharma, Priyanka, Ma, Cynthia, Trivedi, Meghna, Kalinsky, Kevin, Wisinski, Kari B., O’Regan, Ruth, Makhoul, Issam, Spring, Laura M., Bardia, Aditya, Adler, Frederick R., Cohen, Adam L., Chang, Jeffrey T., Khan, Qamar J., Bild, Andrea H.
Publié 2021Texte